Multaq dronedarone regulatory update

sanofi-aventis disclosed that in September its Multaq dronedarone was approved in Switzerland for use in patients with a history of or current atrial fibrillation (AF) or atrial flutter to prevent recurrence or to lower ventricular rate and to reduce the frequency of cardiovascular hospitalization. The company expects to launch the multichannel blocker with properties of antiarrhythmics in Vaughan-Williams classes I-IV in Switzerland next half. ...